ClinicalTrials.gg
RecruitingNCT07933952PDACUpdated Nov 12, 2026

Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance

An observational study in PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Resectable and Pancreatic Adenocarcinoma Metastatic, sponsored by Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Nanjing Medical University · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
30th of 83
300 · median 180
Started
2026
with 61 others
Observational
83 of 485
43 open now
Primary completion
2028-12
later than 229 of 262 live
Registered
484th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 30th largest by planned enrollment of the 83 observational ones that give a count, is one of 62 that started in 2026, is one of 83 observational ones, reaches primary completion later than 229 of the 262 other live ones, and was the 484th registered.

Neoplasm Metastasis

4,045 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, and liver metastasis is a major contributor to treatment failure and reduced survival. Due to the complex mechanisms underlying tumor progression and metastasis, effective early diagnostic biomarkers and targeted therapeutic strategies remain limited. This study aims to investigate the molecular mechanisms underlying PDAC progression and liver metastasis, identify potential biomarkers for early risk prediction and prognostic assessment, and explore novel therapeutic targets to facilitate precision diagnosis and treatment.

Participants will be required to:

  • Provide histopathologically confirmed primary PDAC tissue and liver metastatic tissue, together with the corresponding adjacent non-tumor pancreatic tissue
  • Undergo regular follow-up visits for monitoring and data collection.
  • Allow access to their medical records for relevant clinical information.
Read the detailed description

Registry Procedures and Quality Assurance

As part of this multicenter observational cohort study, investigators will implement standardized patient registration procedures and comprehensive quality assurance measures as follows:

  1. Screening and Recruitment: Eligible patients with pancreatic ductal adenocarcinoma (PDAC) will be identified and recruited through participating hospitals, including pancreatic surgery, oncology, and gastroenterology departments and relevant outpatient clinics and inpatient wards. Patients with synchronous or metachronous liver metastasis, as well as patients without liver metastasis following curative-intent surgical resection, will be included according to the predefined eligibility criteria. Both retrospective clinical data collection and prospective participant recruitment will be conducted in accordance with the approved study protocol. Written informed consent will be obtained from prospective participants or their legally authorized representatives, as applicable.
  2. Data Collection: Clinical data will be collected retrospectively from existing medical records and prospectively through standardized case report forms (CRFs) and longitudinal follow-up. Collected information will include demographic characteristics, medical history, laboratory findings, imaging findings, pathological characteristics, surgical procedures, treatment regimens, metastatic status, and clinical outcomes, including liver metastasis, disease progression, recurrence, and survival. Data entry and verification will be performed by trained research personnel to ensure accuracy, completeness, and consistency across participating centers.
  3. Biospecimen Collection and Quality Control: Biospecimens, including histopathologically confirmed primary pancreatic tumor tissue, liver metastatic tissue when available, corresponding adjacent non-tumor pancreatic tissue, normal liver tissue when available, and peripheral blood-derived samples, will be collected and managed according to the approved study protocol. Standardized operating procedures (SOPs) will be implemented for specimen collection, processing, labeling, transportation, storage, and laboratory testing. Regular data audits, specimen quality assessments, and laboratory quality control procedures will be conducted to ensure sample integrity, traceability, and analytical reliability.
  4. Data Management and Quality Assurance: A standardized data management system and predefined data dictionary will be used across participating centers. Data validation will include completeness assessments, range checks, logical consistency checks, and source data verification where applicable. Regular monitoring and cross-center reviews will be conducted to identify and resolve discrepancies, minimize missing data, and maintain the quality and consistency of clinical and biospecimen-related information.
  5. Data Security and Confidentiality: Participants' privacy and personal information will be strictly protected. Study data and biospecimens will be assigned unique study identification codes, and directly identifiable personal information will be stored separately with restricted access. Electronic data will be maintained in secure, access-controlled systems. All data collection, storage, processing, and sharing procedures will comply with applicable laws, regulations, institutional policies, and ethical requirements.
  6. Ethical Review and Informed Consent: The study will be conducted in accordance with the Declaration of Helsinki and applicable ethical and regulatory requirements. The study protocol will be reviewed and approved by the relevant institutional ethics committee(s) before study implementation. Written informed consent will be obtained from prospective participants or their legally authorized representatives, as applicable. Retrospective data collection and any applicable waiver of informed consent will be conducted only with the approval of the relevant ethics committee(s).
03

Conditions studied

  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Adenocarcinoma Resectable
  • Pancreatic Adenocarcinoma Metastatic
  • Pancreatic Adenocarcinoma Advanced or Metastatic
  • Liver Metastasis

Browse trials for

Keywords

  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Liver Metastases from Pancreatic Ductal Adenocarcinoma
  • Pancreatic adenocarcinoma advanced or metastatic
  • Pancreatic adenocarcinoma Resectable
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of patients with PDAC.Inclusion Criteria:

Aged 18-80 years, regardless of sex; Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging or pathological examination; Voluntary provision of written informed consent (ICF) by the patient or their legally authorized representative; Complete clinical basic information, including: the patient's unique traceability number (ID card number/outpatient number/health insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary PDAC), imaging examination confirmed Liver Metastases from PDAC.

Exclusion Criteria: Presence of other malignant tumors; Receipt of preoperative systemic antitumor therapy (neoadjuvant therapy); Severe cardiac, pulmonary, hepatic, or renal dysfunction; or active infectious diseases; Pregnancy or breastfeeding; Severe coagulation disorders or contraindications to blood collection, or an unacceptably high risk associ

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-80 years, regardless of sex.
  • Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging and/or pathological examination.
  • Meeting at least one of the following criteria:
  • Liver from PDAC confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) at initial diagnosis or during the disease course.
  • No evidence of liver metastasis at initial diagnosis, followed by curative-intent surgical resection and planned postoperative surveillance for liver metastasis.
  • Availability of sufficient clinical information, including demographic characteristics, medical history, imaging and/or pathological findings, treatment information, liver metastasis status, and follow-up outcomes.
  • Availability of a unique study identification code to ensure patient traceability and data linkage.
  • For prospective enrollment and biospecimen collection, voluntary provision of written by the patient or their legally authorized representative, as required by the approved study protocol.

Exclusion criteria

Exclusion Criteria:

  • Concomitant diagnosis of other malignant tumors.
  • Receipt of preoperative systemic antitumor therapy ( therapy) before curative-intent surgical resection, for patients in the resection subgroup.
  • Severe cardiac, pulmonary, hepatic, or renal dysfunction.
  • Active infectious diseases.
  • Pregnancy or breastfeeding.
  • Severe coagulation disorders, to blood collection, or an unacceptably high risk associated with blood collection as assessed by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • PDAC With Liver Metastasis

    This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) with liver metastasis confirmed by contrast-enhanced CT or MRI at initial diagnosis or during treatment. Clinical characteristics, laboratory findings, imaging data, pathological features, treatment information, and follow-up outcomes will be collected. Available biospecimens may include primary pancreatic tumor tissue, liver metastatic tissue, corresponding adjacent non-tumor pancreatic tissue, normal liver tissue, and peripheral blood samples. No study-assigned interventions will be administered, and all diagnostic and therapeutic decisions will follow routine clinical practice.

  • Patients With Pancreatic Ductal Adenocarcinoma

    This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) who meet the predefined eligibility criteria. The cohort includes patients with synchronous liver metastasis at initial diagnosis and those without liver metastasis at baseline who undergo curative-intent surgical resection and are followed for the development of postoperative liver metastasis. Clinical characteristics, pathological findings, imaging data, treatment information, available biospecimens, and longitudinal follow-up outcomes will be collected. The primary outcome is the occurrence of liver metastasis within 12 months after curative-intent resection among eligible patients without liver metastasis at baseline. No study-assigned interventions will be administered, and all treatment decisions will follow routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Occurrence of Liver Metastasis Within 1 Year After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma

    The proportion of patients with pancreatic ductal adenocarcinoma (PDAC) who develop liver metastasis within 1 year after curative-intent surgical resection. Liver metastasis will be assessed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), with pathological confirmation when available. The occurrence of liver metastasis will be recorded as a binary outcome (yes or no).

    Time frame: From the date of curative-intent surgical resection to 12 months postoperatively.

  2. Disease-Free Survival (DFS)

    Disease-free survival (DFS) is the period after treatment during which there is no evidence of active cancer. It is a measure of the effectiveness of treatment in eliminating cancer cells. DFS will be calculated from the time of treatment initiation until the first sign of cancer recurrence or the end of the study.

    Time frame: Monitored and reported at 6 months, 1 year, 2 years, and study completion (up to 5 years).

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is the length of time during and after the treatment of a disease that a patient lives without the disease getting worse. In the context of this study, PFS will be used to measure the time from study entry until the cancer progresses or the patient dies from any cause, providing an intermediate endpoint that reflects the control of disease progression.

    Time frame: Monitored and reported at 6 months, 1 year, 2 years, and annually thereafter (3, 4, and 5 years) after study entry.

  2. Overall Survival (OS)

    Overall survival (OS) is a critical endpoint that measures the length of time from the start of the study until the death of a patient. It provides an assessment of the long-term outcome for patients with liver cancer and will be used to evaluate the prognostic value of the novel protein indicator.

    Time frame: Monitored throughout the study and reported at 1 year, 2 years, and study completion (up to 5 years).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 26 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 12, 2026
StartActual
Oct 22, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Oct 20, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07933952
Responsible party
Yewei Zhang (Chief Physician, Nanjing Medical University) — Principal investigator
First posted
Nov 12, 2026
Start date
Oct 22, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Oct 20, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Yewei Zhang
Contact
zhangyewei@njmu.edu.cn
+86 13813885788

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion